Immune and bone marrow environment changes during the MDS course. Credit: HemaSphere (2024). DOI: 10.1002/hem3.64 Researchers from King’s College have led research that has resulted in the publication of first-of-their-kind guidelines that seek to standardize how clinicians measure the immune response of patients who have myelodysplastic syndromes (MDS), a type of hard to treat blood cancer. The new guidelines, published in HemaSphere, will help hematologists identify which patients could potentially respond to specific types of therapies, and also better categorize patients based on their type of immune response (autoimmune versus Read More